2023 - Research.com Medicine in Spain Leader Award
Miguel A. Sanz mainly investigates Internal medicine, Surgery, Acute promyelocytic leukemia, Leukemia and Chemotherapy. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Immunology and Oncology. In most of his Surgery studies, his work intersects topics such as International Prognostic Scoring System.
His Acute promyelocytic leukemia study also includes fields such as
Internal medicine, Gastroenterology, Surgery, Oncology and Acute promyelocytic leukemia are his primary areas of study. Chemotherapy, Leukemia, Transplantation, Myeloid leukemia and Cumulative incidence are among the areas of Internal medicine where the researcher is concentrating his efforts. His Gastroenterology study integrates concerns from other disciplines, such as Univariate analysis, Incidence, Pathology and Graft-versus-host disease.
His Surgery study frequently draws connections between related disciplines such as Bone marrow. His research in Oncology intersects with topics in Cytarabine, Hematology, Immunology and Myelodysplastic syndromes. Miguel A. Sanz works mostly in the field of Acute promyelocytic leukemia, limiting it down to topics relating to Idarubicin and, in certain cases, Mitoxantrone.
His primary areas of investigation include Internal medicine, Myeloid leukemia, Oncology, Cumulative incidence and Acute promyelocytic leukemia. Miguel A. Sanz combines topics linked to Gastroenterology with his work on Internal medicine. His work deals with themes such as Newly diagnosed, Chemotherapy regimen and Refractory, which intersect with Myeloid leukemia.
Miguel A. Sanz combines subjects such as Cytarabine, Azacitidine, European LeukemiaNet and NPM1 with his study of Oncology. His Cumulative incidence study combines topics from a wide range of disciplines, such as Umbilical Cord Blood Transplantation and Adult patients. His Acute promyelocytic leukemia study combines topics in areas such as Arsenic trioxide, Cancer research, Obstetrics, Fetal viability and Leukemia.
Miguel A. Sanz focuses on Internal medicine, Myeloid leukemia, Acute promyelocytic leukemia, Oncology and Cumulative incidence. His study involves Chemotherapy, Transplantation, Incidence, Hematopoietic stem cell transplantation and Retrospective cohort study, a branch of Internal medicine. His work in the fields of Myeloid leukemia, such as European LeukemiaNet, overlaps with other areas such as Relevant information.
His Acute promyelocytic leukemia research is multidisciplinary, relying on both Cancer research, BAALC, Hyperfibrinolysis, Disease and Leukemia. His work carried out in the field of Oncology brings together such families of science as Cytarabine, Idarubicin and Bone marrow. Miguel A. Sanz works mostly in the field of Cumulative incidence, limiting it down to topics relating to Gastroenterology and, in certain cases, Stroke and Posterior reversible encephalopathy syndrome, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter Greenberg;Christopher Cox;Michelle M. LeBeau;Pierre Fenaux.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero;Roberto Stasi;Terry Gernsheimer;Marc Michel.
International consensus report on the investigation and management of primary immune thrombocytopenia.
Drew Provan;Roberto Stasi;Adrian C. Newland;Victor S. Blanchette.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann.
The New England Journal of Medicine (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding.
The New England Journal of Medicine (2017)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg.
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia
Pierre Fenaux;Claude Chastang;Sylvie Chevret;Miguel Sanz.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: